AMLX holder plans Rule 144 sale of 3,557 shares

Amylyx Pharmaceuticals (AMLX) shareholder James M. Frates filed a Rule 144 notice for a planned sale of 3,557 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 52,097 and 173,547 shares outstanding.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals (AMLX) shareholder James M. Frates filed a Rule 144 notice for a planned sale of 3,557 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 52,097 and 173,547 shares outstanding.

The shares relate to equity compensation: 10,000 common shares were acquired on 02/02/2026 through the vesting of restricted stock units from the issuer, with no separate cash payment. During the prior three months, Frates sold 3,326 common shares on 01/06/2026 for gross proceeds of 36,954. By signing, he represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the AMLX Form 144 filing by James M. Frates disclose?

The filing discloses that James M. Frates plans to sell 3,557 AMLX common shares on NASDAQ through Morgan Stanley Smith Barney. It also notes prior sales of 3,326 shares and that he is unaware of any undisclosed material adverse information about the company.

How many AMLX shares are being proposed for sale under this Rule 144 notice?

The notice covers a proposed sale of 3,557 shares of AMLX common stock with an aggregate market value of 52,097. These shares will be sold on NASDAQ through Morgan Stanley Smith Barney, as disclosed in the Rule 144 securities information table.

How were the AMLX shares in the Form 144 acquired by James M. Frates?

The AMLX common shares were acquired on 02/02/2026 through the vesting of restricted stock units from the issuer. The table lists 10,000 securities acquired on that date, with the nature of acquisition identified as vesting of restricted stock units and payment noted as N/A.

What prior AMLX share sales by James M. Frates are reported in the last three months?

The filing reports that James M. Frates sold 3,326 AMLX common shares on 01/06/2026, generating gross proceeds of 36,954. This transaction is listed in the section covering securities sold during the past three months by the person for whose account the securities are to be sold.

What representation does James M. Frates make about AMLX information in this Form 144?

By signing the notice, he represents that he does not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. This representation is required as part of the Rule 144 filing language.

What is the reported number of AMLX shares outstanding in the Form 144?

The securities information table lists 173,547 AMLX common shares outstanding. This figure provides context for the planned Rule 144 sale of 3,557 shares and is disclosed alongside the aggregate market value and other trade details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:10 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001235598
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Amylyx Pharmaceuticals, Inc.
SEC File Number	001-41199
Address of Issuer	55 Cambridge Parkway Suite 6W Cambridge MASSACHUSETTS 02142
Phone	617-682-0917
Name of Person for Whose Account the Securities are To Be Sold	Frates James M
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza 8th Floor New York NY 10004	3557	52097	173547	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/02/2026	Vesting of Restricted Stock Units	Issuer			10000	02/02/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Frates James M 55 Cambridge Parkway Suite 6W Cambridge MA 02142	Common	01/06/2026	3326	36954

144: Remarks and Signature

Remarks	This sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua B. Cohen, as Attorney in Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)